ArticleFrontiers in bioengineering and biotechnology2025
Novel polyhydroxyalkanoate-graphene oxide composites with potential for clinical application against bacterial implant-associated infections in septic surgery.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exploring the Antimicrobial Efficacy of Graphene Oxide: Key Mechanisms and Future Directions.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Implant-associated infections are a major clinical challenge, often leading to implant failure, revision surgeries, and increased healthcare costs. The development of advanced biomaterials with inherent antimicrobial properties is critical to address this issue. In this study, we present novel two-dimensional (2D) composite films based on polyhydroxyalkanoates (PHAs) combined with graphene oxide (GO) to confer both antimicrobial activity and tailored mechanical properties. Methods: Composites with varying GO concentrations (0.5, 2, and 5 wt%) were fabricated using the solvent casting method, using both a short-chain-length PHA, P(3HB) and a medium-chain-length PHA, P(3HO-co-3HD). Physicochemical characterization (scanning electron microscopy (SEM), X-ray photoelectron spectroscopy (XPS), Raman spectroscopy, X-ray diffraction (XRD), differential scanning calorimetry (DSC), and mechanical testing) confirmed successful GO incorporation, changes in surface morphology, and modifications in thermal and mechanical properties. Results: Notably, the incorporation of 2 wt% GO into P(3HB) increased the Young's modulus from 776 ± 15 MPa to 1,055 ± 28 MPa, indicating enhanced stiffness. Antibacterial testing using ISO 22196 against Staphylococcus aureus and Escherichia coli revealed that P(3HB)/2 wt% GO exhibited the highest antibacterial efficacy. In contrast, the 5 wt% GO composite showed reduced antibacterial activity, likely due to GO agglomeration. Moreover, in vitro cytocompatibility assays using L929 fibroblasts and NG108-15 neuronal cells demonstrated high cell viability across all composites, indicating high cytocompatibility. Discussion/Conclusion: These findings highlight the potential of PHA/GO composites as sustainable, antimicrobial biomaterials for future use in implantable devices for septic surgical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.